Latest Fibrin Stories
KING OF PRUSSIA, Pa., Jan. 16 /PRNewswire/ -- CSL Behring announced today that the U.S.
LEIDEN, The Netherlands, January 13 /PRNewswire/ -- ProFibrix B.V., today announced that it has concluded a commercial license agreement with Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) for PER.C6(R), a unique human protein production platform.
HAE:TSX Skin graft fixation for burn victims using fibrin sealant represents multi-million dollar market opportunity for Company MONTREAL, Dec.
HAE:TSX MONTREAL, Dec.
EMERYVILLE, Calif., Sept. 25 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc.
Omrix Biopharmaceuticals, a fully-integrated biopharmaceutical company, has completed enrollment of the first 90 patients in its Phase II clinical trial for the Fibrin Pad in mild to moderate bleeding. The company expects to release 90 patient interim efficacy analysis by the end of October 2008.
ProFibrix B.V., a Dutch biotech company focused on products to stop bleeding and initiate tissue repair, today announced that it has added Jan Ohrstrom, MD as COO to its Executive Management team. Dr.
CSL Behring has submitted a biologics license application to the FDA requesting approval to market its human fibrinogen concentrate in the US for the treatment of congenital fibrinogen deficiency, a rare bleeding disorder resulting from deficiency of fibrinogen.
Omrix Biopharmaceuticals has enrolled its first patient in a Phase II clinical trial in Israel for its Fibrin Pad product candidate.
Blood clots can save lives, staunching blood loss after injury, but they can also kill. Let loose in the bloodstream, a clot can cause a heart attack, stroke or pulmonary embolism.
- In medieval musical notation, a sign or neume denoting a shake or trill.